Abstract
Ovarian cancer, generally treated with combination first line chemotherapy after cytoreduction surgery [1], has the highest mortality of all invasive cancers of the female reproductive system. CA 125 serum concentration is usually adopted to evaluate the clinical situation in ovarian cancer patients [2]. An approach to rapid evaluation of clinical response and monitoring, instead of using the coarse CA 125 serum concentration, is the determination of tumor marker kinetic parameters, associated with changes in its concentrations, such as half-life (t1/2) and doubling time (DT) [3]. The rate of decline in CA 125 during primary chemotherapy has been an important independent prognostic factor in several multivariate analyses [2]. Several studies report the greatest difference in progression rate, found at a t1/2 of 20
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Gynecology and Obstetrics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
